Eli Lilly Reports P-III (TRIUMPH-2) Results on Retatrutide for Obesity and Type 2 Diabetes

Shots: TRIUMPH-2 assessed retatrutide (4, 9, or 12mg, QW) vs PBO in 1152 pts with T2D & obesity/overweight, with trial using a stepwise dose-escalation approach at Q4W. Lilly plans to file BLA in Q1’27 At 80wks., avg. body weight reductions were 12.7% (4mg), 19.1% (9mg), & 20.8% (12mg) vs 4%, plus A1C reduced by 1.4%,…

ByRidhi Rastogi2 days ago

NEWS

Tolerance Bio and Tanabe Pharma Partner for MT-2990 in Deal With Up to $560M in Milestones

Shots: Tolerance Bio has entered into an exclusive license agreement with Tanabe Pharma for MT-2990, an anti-IL-33 monoclonal antibody, across all indications Tanabe Pharma has granted Tolerance Bio worldwide development & manufacturing rights, and ex-Japan exclusive commercialization rights for MT-2990 (TLB-33), while Tanabe will retain commercialization rights in Japan As per the deal, Tanabe will…

ByRidhi Rastogi2 days ago

NEWS

Egetis Therapeutics Reports the US FDA Approval of Emcitate for MCT8 Deficiency

Shots: The US FDA has approved Emcitate (tiratricol) for the treatment of peripheral thyrotoxicosis in adults & pediatric pts with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome) Approval was supported by an extensive clinical development program assessing Emcitate in pts with MCT8 deficiency, incl. ReTRIACt, Triac Trial I, Triac Trial II, Erasmus Medical Center (EMC)…

ByRidhi Rastogi2 days ago

NEWS

Summit Therapeutics and AstraZeneca Enter $2B Strategic Investment and Oncology Collaboration

Shots: AstraZeneca will invest $2B in Summit through convertible preferred shares, representing a conversion price of $18.36/share, while the companies will collaborate on the development of ivonescimab & sonesitatug vedotin (sone-ve). The clinical collaboration will evaluate ivonescimab with sone-ve in GI cancers, with studies expected to begin soon. Companies will share study costs, while each…

ByRidhi Rastogi3 days ago

NEWS

Teva Reports the US FDA Approval of Degevma (Biosimilar, Xgeva)

Shots: The US FDA has approved Degevma, a biosimilar version of Xgeva (denosumab), following FDA approval of Ponlimsi (biosimilar, Prolia) in Mar 2026, with launch of both biosimilars anticipated in coming mos. Approval was backed by extensive data, incl. analytical & clinical data showing similar efficacy, safety & immunogenicity profile as the reference product Degevma…

ByRidhi Rastogi3 days ago

NEWS

Hengrui Pharma and Novo Ink ~$2.6B Global Licensing Deal for HRS-1596

Shots: Hengrui Pharma has entered into a license agreement with Novo for HRS-1596, a P-I-ready GLP-1 receptor & gastric inhibitory polypeptide receptor dual agonist, with potential for QW oral dosing As per the deal, Novo will obtain exclusive rights to develop, manufacture & commercialize HRS-1596 globally, excl. Mainland China, the Hong Kong SAR, the Macao…

ByRidhi Rastogi3 days ago

NEWS

Innovent Reports NMPA Approval for Jaypirca (Pirtobrutinib) to Treat CLL/ SLL

Shots: The NMPA has approved Jaypirca (100 & 50mg) as a monotx. for the treatment of adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), expanding its use across all lines of therapy & regardless of prior covalent BTK inhibitor treatment Approval was backed by the P-III trials: BRUIN CLL-313 assessed Jaypirca in 282 pts with treatment-naïve…

ByRidhi Rastogi3 days ago

NEWS

Kodiak Sciences Reports P-III (DAYBREAK) Trial Data on Zenkuda and Tabirafusp-ted for wAMD

Shots: Kodiak has reported the P-III (DAYBREAK) trial data assessing Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in parallel vs aflibercept in pts with wet age-related macular degeneration (wAMD) Zenkuda met its 1EP, showing meaningful vision gains & rapid, sustained retinal drying, with 54% of pts achieving 6mos. durability at Yr. 1. tabirafusp-ted also met its vision…

ByRidhi Rastogi3 days ago

NEWS

AbbVie Reports the US FDA Approval of Juvmo (Tavapadon) for Parkinson’s Disease

Shots: FDA approval was based on the P-III (TEMPO) program, which evaluated Juvmo in early PD pts not taking oral levodopa (TEMPO-1 & 2) & as an adjunct to oral levodopa vs PBO + levodopa in PD pts with motor fluctuations (TEMPO-3) At Wk. 26 in TEMPO-1, Juvmo showed MDS-UPDRS Part II scores of −1.6…

ByRidhi Rastogi3 days ago

NEWS

Merck and SciBrunch Sign ~$2.13B Exclusive Global License Agreement for SPR2015

Shots: Merck & SciBrunch have entered into an exclusive global license agreement for SPR2015, with Merck receiving exclusive rights to develop, manufacture & commercialize SPR2015 worldwide As per the deal, SciBrunch will receive ~$400M upfront & payment associated with development, commercialization & other milestones across multiple indications, representing the total deal value of ~$2.13B SPR2015…

ByRidhi Rastogi4 days ago

Ridhi Rastogi

Eli Lilly Reports P-III (TRIUMPH-2) Results on Retatrutide for Obesity and Type 2 Diabetes

Tolerance Bio and Tanabe Pharma Partner for MT-2990 in Deal With Up to $560M in Milestones

Egetis Therapeutics Reports the US FDA Approval of Emcitate for MCT8 Deficiency

Summit Therapeutics and AstraZeneca Enter $2B Strategic Investment and Oncology Collaboration

Teva Reports the US FDA Approval of Degevma (Biosimilar, Xgeva)

Hengrui Pharma and Novo Ink ~$2.6B Global Licensing Deal for HRS-1596

Innovent Reports NMPA Approval for Jaypirca (Pirtobrutinib) to Treat CLL/ SLL

Kodiak Sciences Reports P-III (DAYBREAK) Trial Data on Zenkuda and Tabirafusp-ted for wAMD

AbbVie Reports the US FDA Approval of Juvmo (Tavapadon) for Parkinson’s Disease

Merck and SciBrunch Sign ~$2.13B Exclusive Global License Agreement for SPR2015

Contact US

FOLLOW US